Skip to main content
. 2018 Oct 17;36(34):3388–3395. doi: 10.1200/JCO.2017.76.4720

Fig 4.

Fig 4.

Impact of residual disease on overall survival (OS) for patients with molecularly classified supratentorial embryonal tumor (ET)/pineoblastoma (PBL) tumors. Estimated OS at 3 years for patients with molecularly defined supratentorial ET/PBL tumors who had minimal residual disease was 93.8% (95% CI, 81.5% to 100%) compared with and OS of 75.0% (95% CI, 47.2% to 100%) for patients with > 1.5 cm2 of residual disease (P = .012).